Brief: Clarity Pharmaceuticals Expands Supply Of Cu-64 Sar-Bispsma For Pivotal Phase Iii Clinical Trials
14/06/2023 02:29
June 14 (Reuters) - Clarity Pharmaceuticals Ltd
CU6.AX :
* EXPANDS SUPPLY OF CU-64 SAR-BISPSMA FOR PIVOTAL PHASE III
CLINICAL TRIALS
Source text for Eikon: ID:nASX2LDhyH
Further company coverage: CU6.AX
Recent news on Clarity Pharmaceuticals
See all newsBrief: Clarity Pharmaceuticals Signs Commercial Manufacturing Agreement
Brief: Clarity Signs A Large-Scale Manufacturing Supply Agreement For Copper-64 With Theragenics
Brief: Clarity Pharmaceuticals Signs A Large-Scale Manufacturing Supply Agreement
Australia's Clarity Pharmaceuticals rises on bagging cancer detection agent supply
Australia's Clarity Pharma surges as US FDA approves trial